Table 4.

Multivariate Analysis of Combined MDM2 and Ki-67 Marker Data

Covariate by End Point	Multivariate Analysis
	HR	95% CI	P *
DM
Age ≥ 70 years	0.57	0.37 to 0.90	.02
GLSC
7	1.21	0.60 to 2.36	.57
8-10	3.85	2.14 to 6.93	< .0001
iPSA > 30 ng/mL	1.34	0.88 to 2.05	.17
Clinical stage T3-4	1.77	1.12 to 2.79	.01
Assigned treatment of STAD + RT	2.13	1.37 to 3.32	.0009
p53 manual PSP > 0	1.05	0.68 to 1.63	.82
Ki-67 PSP and MDM2 MIS
≤ 11.3% and > 184	1.54	0.79 to 2.99	.20
> 11.3% and ≤ 184	2.75	1.57 to 4.82	.0004
> 11.3% and > 184	5.12	2.93 to 8.97	< .0001
CSM
Age ≥ 70 years	0.62	0.38 to 1.00	.052
GLSC
7	1.28	0.64 to 2.57	.49
8-10	3.65	1.95 to 6.84	< .0001
iPSA > 30 ng/mL	1.12	0.70 to 1.78	.64
Clinical stage T3-4	2.50	1.50 to 4.17	.0004
Assigned treatment of STAD + RT	2.07	1.27 to 3.36	.003
p53 manual PSP > 0	0.87	0.54 to 1.39	.55
Ki-67 PSP and MDM2 MIS
≤ 11.3% and > 184	1.49	0.74 to 2.97	.26
> 11.3% and ≤ 184	2.27	1.21 to 4.26	.01
> 11.3% and > 184	3.68	1.94 to 6.95	< .0001
ΟΜ
Age ≥ 70 years	1.59	1.22 to 2.06	.0005
GLSC
7	1.58	1.15 to 2.18	.005
8-10	1.15	0.88 to 1.50	.31
iPSA > 30 ng/mL	1.12	0.81 to 1.50	.50
Clinical stage T3-4	1.26	0.97 to 1.64	.08
Assigned treatment of STAD + RT	1.26	0.98 to 1.63	.08
p53 Manual PSP > 0	0.72	0.55 to 0.95	.02
Ki-67 PSP and MDM2 MIS
≤ 11.3% and > 184	1.62	1.13 to 2.31	.009
> 11.3% and ≤ 184	1.50	1.06 to 2.12	.02
> 11.3% and > 184	2.14	1.43 to 3.20	.0002

NOTE. Multivariate analyses were performed on 446 patient cases.

Abbreviations: HR, hazard ratio; DM, distant metastasis; GLSC, Gleason score; STAD, short-term androgen deprivation; RT, radiation therapy; PSP, percent staining positive; MIS, mean intensity score; CSM, cause-specific mortality; OM, overall mortality.

^*P values are from Fine and Gray's regression model for CSM and DM and from the Cox regression model for OM.